A Phase 4 interventional study of First patient Bupivacaine liposome and next patient Bupivacaine liposome in Motion Sickness, sponsored by Affiliated Hospital of Jiaxing University. Completed at 1 site in China. Open to participants aged 41 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-29.
Sponsored by Affiliated Hospital of Jiaxing University · Phase 4, Interventional, and Diagnostic
Explore the minimum effective dose of liposomal bupivacaine for preserving motor function
Our research group plans to conduct a dose exploration experiment, using a biased coin design sequential method to explore the 90% minimum effective dose of bupivacaine liposomes for preserving motor function after intermuscular groove brachial plexus block surgery in shoulder arthroscopy.
50 studies on the registry are indexed under Motion Sickness; 9 are open to participants now.
This study's enrollment of 55 is close to the median of 59 across 44 interventional studies indexed under Motion Sickness.
Browse Motion Sickness studies →Affiliated Hospital of Jiaxing University is the lead sponsor of 17 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age 41-65 years ASA physical condition 1-3 18-30 kg/m2 undergoing arthroscopic shoulder surgery
Exclusion Criteria:
Inability to consent to the study pregnancy allergy to local anesthetics preexisting neuropathy cervical pathologies (i.e., herniated disc, myelopathy) chronic pain syndromes (defined as reflex sympathetic dystrophy or complex regional pain syndrome) severe respiratory conditions psychiatric or cognitive disorders that prohibit patients from adhering to the study protocol history of drug or alcohol abuse chronic opioid use (longer than 3 months or daily morphine equivalents more than 5mg/day for 1 month) for general anesthesia and/or interscalene nerve block and planned open shoulder arthrotomies Muscle related diseases
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First patient's use of bupivacaine liposome and next patient's use of bupivacaine liposome
Drug: First patient Bupivacaine liposome and next patient Bupivacaine liposome
First patient's use of bupivacaine liposome and next patient's use of bupivacaine liposome
Drug: First patient Bupivacaine liposome and next patient Bupivacaine liposome
This study was conducted using the biased coin method, where each patient's use of bupivacaine liposome dose depended on the previous patient's response. Based on previous research and our past experience, the first recruited patient used a dose of 66.5mg (15ml). Subsequently, if motor function was preserved, the next patient received a higher dose (increased by 6.65mg) with a probability of b=0.11; or the same dose with a probability of 1-b=0.89. If motor function was blocked, the next patient received a lower dose (decreased by 6.65mg).
ED90 of motor function was preserved 72 hours after brachial plexus block
Evaluate the effective sensory blockade for maintaining motor function at the time point
Time frame: 72 hours after brachial plexus block
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Affiliated Hospital of Jiaxing University